观察术后不同时间腹腔热灌注化疗对卵巢癌患者肿瘤标志物水平的影响。

选取2018年6月~2020年12月柳州市工人医院收治的84例卵巢癌患者纳入研究对象，抽签随机分为观察组与对照组，各42例。2组患者卵巢癌根治术后均接受腹腔热灌注化疗，观察组患者于术后24 h开始第一次腹腔热灌注化疗，并按每24 h一次进行重复灌注；对照组患者于术后48 h开始第一次腹腔热灌注化疗，并按每48 h一次进行重复灌注，4次为1个疗程，2组均治疗1个疗程。比较2组治疗效果及化疗期间不良反应，比较2组治疗前后肿瘤标志物、T淋巴细胞水平，2组患者治疗后均行1年随访观察，比较2组患者的存活率。

观察组客观缓解率、疾病控制率分别为90.48%、95.24%显著高于对照组71.43%、80.95%（P＜0.05）；2组治疗后VEGF、HE-4、CA125水平显著低于治疗前（P＜0.05），观察组治疗后VEGF、HE-4、CA125水平显著低于对照组（P＜0.05）；2组治疗后CD3⁺、CD4⁺、CD4⁺/CD8⁺水平显著高于治疗前，CD8⁺水平显著低于治疗前（P＜0.05），2组治疗后CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺水平比较差异无统计学意义（P＞0.05）；2组治疗期间不良反应总发生率差异无统计学意义（P＞0.05）；观察组和对照组1年生存率分别为92.68%、90.00%，Kaplan-Meier生存分析显示2组1年生存率无明显差异（Log Rank=0.191，P=0.662）。

术后每24 h进行一次腹腔热灌注化疗卵巢癌患者肿瘤标志物水平降低更明显。

To observe the effect of intraperitoneal hyperthermic perfusion chemotherapy at different times after operation on the levels of tumor markers in patients with ovarian cancer.

A total of 84 ovarian cancer patients admitted to Liuzhou Workers hospital from June 2018 to December 2020 were selected as the study subjects, and they were randomly divided into either an observation group or a control group, with 42 cases in each group. Both groups of patients received intraperitoneal hyperthermic perfusion chemotherapy after radical resection of ovarian cancer. Patients in the observation group started their first intraperitoneal hyperthermic perfusion chemotherapy at 24 h after surgery, and repeated perfusion was performed every 24 h. Patients in the control group started the first intraperitoneal hyperthermic perfusion chemotherapy at 48 hours after the operation, and repeated infusion was performed every 48 hours. Both groups received a cycle of treatment consisting of 4 sessions of chemotherapy. Therapeutic effects and adverse reactions during chemotherapy were compared between the two groups. The levels of tumor markers and T lymphocytes in the two groups before and after treatment were also compared. After treatment, both groups of patients underwent a 1-year follow-up observation to calculate the survival rates of the two groups.

The objective remission rate and disease control rate of the observation group were 90.48% and 95.24%, respectively, which were significantly higher than those of the control group (71.43% and 80.95%, respectively, P＜0.05). The levels of VEGF, HE-4, and CA125 after treatment were significantly lower than those before treatment in both groups (P＜0.05), and the levels of VEGF, HE-4 and CA125 in the observation group were significantly lower than those in the control group after treatment (P＜0.05). The levels of CD3⁺ T cells, CD4⁺ T cells, and CD4⁺/CD8⁺ ratio after treatmen were significantly higher than those before treatment in both groups, and the level of CD8⁺ T cells was significantly lower than that before treatment (P＜0.05). There was no significant difference in the level of CD3⁺ T cells, CD4⁺ T cells, CD8⁺ T cells, or CD4⁺/CD8⁺ rate between the two groups after treatment (P＞0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups during treatment (P＞0.05). The 1-year survival rates of the observation group and the control group were 92.68% and 90.00%, respectively. Kaplan-Meier survival analysis showed that there was no significant difference in 1-year survival rates between the two groups (Log rank=0.191, P=0.662).

The levels of tumor markers in patients with ovarian cancer receiving intraperitoneal hyperthermic perfusion chemotherapy every 24 hours after the operation decline more obviously.